| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648394 | SKINMEDICA | Topical composition for inhibiting hair growth |
Jul, 2014
(9 years ago) | |
Vaniqa is owned by Skinmedica.
Vaniqa contains Eflornithine Hydrochloride.
Vaniqa has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Vaniqa are:
- US5648394
Vaniqa was authorised for market use on 27 July, 2000.
Vaniqa is available in cream;topical dosage forms.
Vaniqa can be used as treatment of excessive female facial hair.
The generics of Vaniqa are possible to be released after 15 July, 2014.
Drugs and Companies using EFLORNITHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 July, 2000
Treatment: Treatment of excessive female facial hair
Dosage: CREAM;TOPICAL
More Information on Dosage
VANIQA family patents
